Vinblastine - Therapeutic use
Research News and Information

Monday, November 23, 2009

Nodular lymphocyte predominant Hodgkin lymphoma with clusters of LP Cells, acute inflammation, and fibrosis: a syncytial variant.

30 Oct 2009 Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has clinicopathologic, immunophenotypic, and molecular features that are distinct from classical Hodgkin lymphoma (cHL). Distinguishing these entities is usually straightforward, but unusual ... Read more...

Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study.

29 Sep 2009 BACKGROUND: A Phase II trial was developed to determine the efficacy and toxicity of intravenous vinorelbine, a semi-synthetic vinca alkaloid, in children, adolescent, and young adults with recurrent or refractory solid malignancies. PROCEDURES: ... Read more...

Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.

13 Sep 2009 BACKGROUND: The activity and safety of vinflunine was evaluated in patients with locally advanced or metastatic urothelial carcinoma (UC) who developed disease progression within 12 months of platinum-containing chemotherapy. METHODS: Patients with ... Read more...

Latest indexed articles for 'Vinblastine - Therapeutic use'

These are the very latest articles for this heading:

• Nodular lymphocyte predominant Hodgkin lymphoma with clusters of LP Cells, acute inflammation, and fibrosis: a syncytial variant. 30 Oct 2009
• Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study. 29 Sep 2009
• Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. 13 Sep 2009
• Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. 13 Sep 2009
• Unintended pregnancy after gonadal failure chemoprevention with gonadotropin-releasing hormone agonist in women with hematologic malignancies. Sep 2009
• Second-line therapy in bladder cancer. 30 Aug 2009
• Bisphenol, npcRNAs and Utero-Ovarian Feed-Back Control of Breast Cancer Chemosensitivity. 30 Jul 2009
• Langerhans cell histiocytosis, a case of Letterer Siwe disease. 29 Jun 2009
• Acute promyelocytic leukemia after Stanford V plus radiotherapy for advanced Hodgkin lymphoma. 29 Jun 2009
• Capecitabine and vinorelbine in metastatic breast cancer. 18 May 2009
• [Inaugural trunk dystonia revealing Langerhans cell histiocytosis] 7 May 2009
• Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. 29 Apr 2009
• [Use of M-VAC in the adjuvant treatment of sarcomatoid carcinoma of the bladder] 30 Mar 2009
• Gefitinib in the treatment of advanced non-small-cell lung cancer. 30 Mar 2009
• [Effects and toxicity of neoadjuvant chemotherapy with vinorelbine and cisplatin in treatment of operable breast cancer previously non-responsive to anthracyclines and taxanes-containing regimen: analysis of 19 cases] 15 Mar 2009
• Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium. 9 Mar 2009
• Role of radiation therapy in Hodgkin's lymphoma. 27 Feb 2009
• Combined modality treatment of Hodgkin's lymphoma. 27 Feb 2009
• Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer. 27 Feb 2009
• Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. 13 Feb 2009

See a longer list of these articles.

Technical information about 'Vinblastine'

Definition: Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

Registry Number: 865-21-4

Descriptor UI: D014747

Alternative terms: Vinblastine; Vincaleukoblastine; Gastrozepin Brand of Vinblastine Sulfate; Faulding Brand of Vinblastine Sulfate; Vinblastinsulfat-Gry; Gry Brand of Vinblastine Sulfate; Velban; Vinblastina Lilly; Velbe; EG Labo Brand of Vinblastine Sulfate; Lilly Brand of Vinblastine Sulfate; Vinblastin Hexal; Hexal Brand of Vinblastine Sulfate; Vinblastine Sulfate; Sulfate, Vinblastine; cellblastin; cell pharm Brand of Vinblastine Sulfate; Lemblastine; Lemery Brand of Vinblastine Sulfate;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists; biosynthesis;

Pharmacological Action: Antineoplastic Agents, Phytogenic; Tubulin Modulators;

Tree Number: D03.132.436.681.827.650; D03.438.473.402.681.827.650;

Technical Notes: /biosyn permitted if by plant